FASgen Secures $2.5 Million for TB Drug Development

FASgen has been awarded a $500,000 grant from the U.S. National Institutes of Health for completion of the final preclinical safety and animal efficacy work in support of the investigational new drug application for FAS20013 in MDR-TB. At the same time, the company has secured a $2 million investment from a private investor to support the MDR-TB (multiple drug-resistant tuberculosis) drug development and clinical trial program.